BigCapital beta

Moscow Exchange · ABIO · IFRS

Artgen biotekh: revenue, profit and cash flow

In 2024, Artgen biotekh had revenue of ₽1.52B and a net profit of ₽215M, according to its consolidated IFRS statements. Here: 12 years of annual reports since 2012, each linked to the original document.

Revenue, 2024

₽1.52B+11.2%

change against 2023

Net profit
₽215M
attributable to shareholders · 14.1% of revenue
Earnings per share, 2024
₽2.32
Operating cash flow
₽482M
Capital expenditure
₽99.7M
Free cash flow
₽382M
operating cash flow minus capital expenditure
Net debt
₽64.9M
borrowings minus cash; leases not included
Dividends paid
₽141M
Total assets
₽2.67B
Equity
₽407M

Where the money goes

Of every ₽100 of revenue in 2024, Artgen biotekh spent ₽80.2 on costs and expenses; ₽7.2 went to interest and other items, a tax benefit added ₽1.6, and ₽14.1 was left as net profit.

2024 · rubles · share of revenue
In 2024AmountOf revenue
Revenue₽1.52B100.0%
Costs and expenses−₽1.22B80.2%
Operating profit₽301M19.8%
Tax benefit₽23.7M1.6%
Interest and other, net−₽110M7.2%
Net profit₽215M14.1%

Revenue and net profit

Revenue went from ₽300M in 2012 to ₽1.52B in 2024. Net loss in 2012, 2014–2016, 2018.

RevenueNet profit
Rubles, as reported (IFRS); years without a report are left out.

Earnings per share

Basic earnings per share went from −₽1.44 in 2012 to ₽2.32 in 2024.

Years · rubles per share, basic, adjusted for share splits

Operating cash flow, capex and free cash flow

Free cash flow (operating cash flow minus capital expenditure) was ₽382M in 2024, 25.1% of revenue. Negative in 2012, 2015–2016, 2018–2020.

Operating cash flowCapital expenditureFree cash flow
Rubles, as reported (IFRS); years without a report are left out.

What it owns and who paid for it

At the end of 2024, Artgen biotekh had ₽2.67B of assets, ₽503M of it in cash. They were paid for by ₽568M of borrowings, ₽1.7B of other liabilities and ₽407M of shareholders' equity: equity is 15.3% of the assets.

End of 2024 · rubles · share of assets · sizes across years on a square-root scale

Net debt

Net debt (borrowings minus cash) was ₽64.9M at the end of 2024. That is 0.2 times its EBITDA of ₽386M (operating profit plus depreciation and amortisation).

Net debt
Rubles, as reported (IFRS); years without a report are left out.

Dividends paid

In 2024, Artgen biotekh paid ₽141M in dividends, 65% of its net profit for the year.

Dividends paid
Rubles, as reported (IFRS); years without a report are left out.

Artgen biotekh: annual figures

YearRevenueOperating profitNet profitBasic EPSOperating cash flowCapital expenditureFree cash flowNet debtDividends paidTotal assetsEquity
2024₽1.52B₽301M₽215M₽2.32₽482M₽99.7M₽382M₽64.9M₽141M₽2.67B₽407M
2023₽1.37B₽276M₽169M₽1.82₽435M₽204M₽231M₽103M₽104M₽2.54B₽500M
2022₽1.14B₽111M₽46.1M₽0.53₽220M₽136M₽84.4M₽507M₽40.1M₽2.04B₽341M
2021₽1.18B₽119M₽11.6M₽0.16₽281M₽153M₽128M₽301M₽30.9M₽1.74B₽235M
2020*₽1.08B₽198M₽72.9M₽0.97₽53.9M₽85.6M−₽31.7M₽246M₽12.7M₽1.51B₽194M
2019₽836M₽181M₽84.6M₽1.48₽176M₽196M−₽20.5M₽192M—₽1.4B₽98.7M
2018*₽645M₽117M−₽34.2M−₽0.24₽19.4M₽35.3M−₽15.9M₽308M—₽1.12B₽27M
2016₽390M−₽144M−₽111M−₽1.75₽36M₽66.9M−₽30.9M₽60.7M₽21.3M₽1.04B₽154M
2015*₽311M−₽95.5M−₽51.5M−₽0.83₽4.6M₽19.3M−₽14.7M₽63.9M₽0₽833M₽288M
2014₽359M−₽51.3M−₽13.2M−₽0.22₽38.2M₽32.9M₽5.37M₽27.5M—₽806M₽339M
2013₽420M₽42.7M₽14.7M₽0.22₽82.5M₽34.5M₽48M₽109M—₽729M₽352M
2012*₽300M−₽32.6M−₽109M−₽1.44−₽55.5M₽32.1M−₽87.6M₽123M—₽683M₽337M

* Taken from the comparative column of the next year's report: the year's own report was not available to us.

Original reports

Every figure on this page comes from the company's own annual statements. The documents, by year:

How to read these numbers

Source: annual financial statements published by Artgen biotekh (links to the original documents above). Figures read from the documents by BigCapital.

For information only, not investment advice.

Language

EnglishBahasa IndonesiaDeutschEspañolFrançaisItalianoNederlandsPolskiPortuguêsTürkçeРусскийУкраїнська日本語한국어简体中文